Japan's Takeda signs MoU with BIRAC to support healthcare startups

Japanese drug maker Takeda on Tuesday entered into a three-year memorandum of understanding (MoU) with the Biotechnology Industry Research Assistance Council (BIRAC) to foster healthcare innovation.

BIRAC is the funding agency under the department of biotechnology, government of India, that provides financial and technical assistance to biotech and life sciences start-ups.

The partnership will allow Takeda to extend advisory and mentoring support to innovators and entrepreneurs while assisting them from ideation to market deployment of new-age healthcare solutions, the Japanese drug maker said in a statement.


“India is a vibrant and promising healthcare market. The country’s healthcare segment offers an incredible opportunity both for innovation and growth," said Sanjay Patel, global head of Data Digital and Technology Innovation Capability Solutions, Takeda Pharmaceuticals International AG.

"The entrepreneurial spirit of domestic healthcare startups has the power to drive healthcare advancements not only in India but globally," Patel added.

The partnership was announced at the Global Bio-India (GBI) 2023 event organized by the Department of Biotechnology (DBT).